Text Size

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: Experience through the French early-access program

Pisella P.-J., Labetoulle M., Doan S., Cochener-Lamard B., Amrane M., Ismail D., Creuzot-Garcher C., Baudouin C.

  • 2018
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Tours University Hospital, University François Rabelais, Bretonneau Hospital, Tours, France; Department of Ophthalmology, Bicêtre Hospital, APHP, Paris-Sud University, Le Kremlin-Bicêtre, France; Department of Ophthalmology, Bichat Hospital, Fondation A de Rothschild, Paris, France; Brest University Medical School, Morvan Hospital, Brest, France; Santen SAS, Evry, France; Department of Ophthalmology, University Hospital, France; Department of Ophthalmology III, Eye and Nutrition Research Group, Burgundy, Dijon, France; Research Team S12, Quinze-Vingts National Ophthalmology Hospital, France; Department of Ophthalmology, Ambroise-Paré Hospital, APHP, UPMC University, Paris 6, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France

Related Publications

Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits

Mochizuki T.; Hata T.; Mori N.; Yamazaki T.; Noto T.; Mano H.

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022